Live Breaking News & Updates on மாட்ரிகல் மருந்துகள்

Stay updated with breaking news from மாட்ரிகல் மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Stock picks that could be next Gamestop, high short interest and squeeze targets: GS


This story is available exclusively to Insider subscribers.
Become an Insider and start reading now.
Goldman Sachs says Americans have added $1 trillion to money market mutual funds in the pandemic.
That means retail traders influence on the market should only grow in the months ahead.
Goldman says that money could continue to blow up big short bets, just like it did with GameStop.
The GameStop short squeeze and stock bonanza might have felt like a once-a-decade or once-in-a-lifetime event, but Goldman Sachs says it could happen again, and soon.
Even if there were many ways the social media-fueled frenzy in GameStop and AMC Networks and Bed Bath & Beyond was unique, many of its most notable ingredients are still there, according to Goldman Sachs. Chief among them are these two: There are a lot of big short bets on the market, and retail investors still have a ton of money. ....

National Beverage , Goldman Sachs , Seritage Growth Properties , Intercept Pharmaceuticals , Petmed Express , Tootsie Roll Industries , Rocket Companies , Inovio Pharmaceuticals , Bigcommerce Holdings , Ligand Pharmaceuticals , Academy Sports , Tanger Factory Outlet Centers , Madrigal Pharmaceuticals , International Flavors Fragrances , Bed Bath Beyond , Factory Outlet , Bi Prime , Stocks 2021 , Stock Market , Stock Recommendations , Investing Recommendations , Retail Investing , Day Trading , Best Stocks To Buy , Short Squeeze , Short Selling ,

$27.2 Billion Non-Alcoholic Steatohepatitis (NASH) Opportunity Analysis and Forecasts to 2029 – ResearchAndMarkets.com


ResearchAndMarkets.com’s offering.
Sales for the NASH market to grow from $144.4M in 2019 to $27.2B in 2029 at a Compound Annual Growth Rate (CAGR) of 68.8% across the 7MM.
At the end of 2029, the US will contribute around 94.3% of global sales, while the 5EU and Japan will account for around 4.5% and 1.2% of sales, respectively.
Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage. Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem. However, symptoms including fatigue, weight loss, and weakness emerge once the disease has progressed to a more advanced stage, like cirrhosis. NASH is suspected if elevated liver enzymes are detected during routine blood panels, but ....

United Kingdom , Abbvie Allergan , Inventiva Pharma , Laura Wood , Novo Nordisk Ozempic , Office Hours Call , Madrigal Pharmaceuticals , Galmed Pharmaceuticals , E St Office Hours Call , Biopharmaceuticals Inc , Intercept Pharmaceuticals , Bristol Myers Squibb , Novo Nordisk , Alcoholic Steatohepatitis , Opportunity Analysis , Compound Annual Growth Rate , Topics Covered , Executive Summary , Growth Expected , Successive Drug Approvals , Approaches Will Become , Key Strategy , Unmet Need Remains Significant , Non Invasive Tests , Pipeline Products Demonstrating High Levels , Acquire Large Market Share ,